The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Dipyridamole 200mg/5ml Oral Suspension

Syri Pharma Limited t/a Thame LaboratoriesPA22697/009/001

Main Information

Trade NameDipyridamole 200mg/5ml Oral Suspension
Active SubstancesDipyridamole
Dosage FormOral suspension
Licence HolderSyri Pharma Limited t/a Thame Laboratories
Licence NumberPA22697/009/001

Group Information

ATC CodeB01AC Platelet aggregation inhibitors excl. heparin
B01AC07 dipyridamole


Licence Issued15/01/2016
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version
« Back